Cargando…

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?

Amyloid plaques are pathological hallmarks of Alzheimer’s Disease (AD) and biomarkers such as cerebrospinal fluid (CSF) β-amyloid 1–42 (Aβ1-42) and amyloid positron emission tomographic (PET) imaging are important in diagnosing amyloid pathology in vivo. ɛ4 allele of the Apolipoprotein E gene (ApoE...

Descripción completa

Detalles Bibliográficos
Autores principales: Ba, Maowen, Kong, Min, Li, Xiaofeng, Ng, Kok Pin, Rosa-Neto, Pedro, Gauthier, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112745/
https://www.ncbi.nlm.nih.gov/pubmed/27891223
http://dx.doi.org/10.1186/s40035-016-0067-z
_version_ 1782468065398620160
author Ba, Maowen
Kong, Min
Li, Xiaofeng
Ng, Kok Pin
Rosa-Neto, Pedro
Gauthier, Serge
author_facet Ba, Maowen
Kong, Min
Li, Xiaofeng
Ng, Kok Pin
Rosa-Neto, Pedro
Gauthier, Serge
author_sort Ba, Maowen
collection PubMed
description Amyloid plaques are pathological hallmarks of Alzheimer’s Disease (AD) and biomarkers such as cerebrospinal fluid (CSF) β-amyloid 1–42 (Aβ1-42) and amyloid positron emission tomographic (PET) imaging are important in diagnosing amyloid pathology in vivo. ɛ4 allele of the Apolipoprotein E gene (ApoE ɛ 4), which is a major genetic risk factor for late onset AD, is an important genetic biomarker for AD pathophysiology. It has been shown that ApoE ɛ 4 is involved in Aβ deposition and formation of amyloid plaques. Studies have suggested the utility of peripheral blood ApoE ɛ 4 in AD diagnosis and risk assessment. However it is still a matter of debate whether ApoE ɛ 4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβ in resource-limited settings in late onset AD. Recent research suggest that the mean prevalence of PET amyloid-positivity is 95% in ApoE ɛ 4-positive AD patients. This short review aims to provide an updated information on the relationship between ApoE ɛ 4 and amyloid biomarkers.
format Online
Article
Text
id pubmed-5112745
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51127452016-11-25 Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease? Ba, Maowen Kong, Min Li, Xiaofeng Ng, Kok Pin Rosa-Neto, Pedro Gauthier, Serge Transl Neurodegener Review Amyloid plaques are pathological hallmarks of Alzheimer’s Disease (AD) and biomarkers such as cerebrospinal fluid (CSF) β-amyloid 1–42 (Aβ1-42) and amyloid positron emission tomographic (PET) imaging are important in diagnosing amyloid pathology in vivo. ɛ4 allele of the Apolipoprotein E gene (ApoE ɛ 4), which is a major genetic risk factor for late onset AD, is an important genetic biomarker for AD pathophysiology. It has been shown that ApoE ɛ 4 is involved in Aβ deposition and formation of amyloid plaques. Studies have suggested the utility of peripheral blood ApoE ɛ 4 in AD diagnosis and risk assessment. However it is still a matter of debate whether ApoE ɛ 4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβ in resource-limited settings in late onset AD. Recent research suggest that the mean prevalence of PET amyloid-positivity is 95% in ApoE ɛ 4-positive AD patients. This short review aims to provide an updated information on the relationship between ApoE ɛ 4 and amyloid biomarkers. BioMed Central 2016-11-16 /pmc/articles/PMC5112745/ /pubmed/27891223 http://dx.doi.org/10.1186/s40035-016-0067-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Ba, Maowen
Kong, Min
Li, Xiaofeng
Ng, Kok Pin
Rosa-Neto, Pedro
Gauthier, Serge
Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
title Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
title_full Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
title_fullStr Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
title_full_unstemmed Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
title_short Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
title_sort is apoe ɛ 4 a good biomarker for amyloid pathology in late onset alzheimer’s disease?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112745/
https://www.ncbi.nlm.nih.gov/pubmed/27891223
http://dx.doi.org/10.1186/s40035-016-0067-z
work_keys_str_mv AT bamaowen isapoeɛ4agoodbiomarkerforamyloidpathologyinlateonsetalzheimersdisease
AT kongmin isapoeɛ4agoodbiomarkerforamyloidpathologyinlateonsetalzheimersdisease
AT lixiaofeng isapoeɛ4agoodbiomarkerforamyloidpathologyinlateonsetalzheimersdisease
AT ngkokpin isapoeɛ4agoodbiomarkerforamyloidpathologyinlateonsetalzheimersdisease
AT rosanetopedro isapoeɛ4agoodbiomarkerforamyloidpathologyinlateonsetalzheimersdisease
AT gauthierserge isapoeɛ4agoodbiomarkerforamyloidpathologyinlateonsetalzheimersdisease